Monoclonal Antibodies
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
40
NCT06925919
Study to Evaluate Safety, Tolerability and Pharmacokinetics of IDB-011
Phase: Phase 1
Role: Lead Sponsor
Start: Apr 2, 2025
Completion: Oct 31, 2026
Loading map...